Related Experiment Video
Updated: Sep 28, 2025

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Acute Ischemic Stroke in Children - Should We Thrombolyze?
K P Vinayan1, Vivek Nambiar2, Vaishakh Anand1
1Department of Pediatric Neurology, Division of Stroke Medicine, Amrita Institute of Medical Sciences, Cochin, Kerala, India.
Insights
Acute ischemic stroke in children presents challenges due to varied symptoms. While case reports show benefits of tissue plasminogen activator (tPA) thrombolysis, more pediatric trials are needed for guideline development.
Area of Science:
- Pediatric Neurology
- Emergency Medicine
- Thrombotic Stroke Management
Background:
- Ischemic stroke in children causes acute neurological symptoms and long-term sequelae.
- Pediatric stroke presentation is heterogeneous, complicating diagnosis and mimicking other conditions.
- Acute thrombolysis is rarely used in children due to diagnostic challenges and lack of age-specific data.
Purpose of the Study:
- To review the current status of acute ischemic stroke management in children.
- To emphasize the role and challenges of thrombolytic therapy in pediatric stroke.
- To highlight the need for evidence-based guidelines and institutional pathways.
Main Methods:
- Critical review of existing literature on acute ischemic stroke management in children.
- Focus on case reports and limited trials regarding thrombolytic therapy (e.g., tPA).
- Analysis of barriers to guideline development and clinical trial implementation.
Main Results:
- Case reports suggest positive outcomes with timely intravenous thrombolysis using tPA in children.
- Endovascular interventions are also emerging as treatment options.
- Lack of large-scale, pediatric-specific clinical trials and safety data hinders guideline creation.
Conclusions:
- Despite promising case reports, robust clinical trials (RCTs) for pediatric stroke thrombolysis are absent.
- The premature termination of the TIPS trial underscores enrollment challenges.
- Developing institutional pathways is crucial for providing timely thrombolysis to eligible children until evidence-based guidelines are established.
Abstract:
Ischemic stroke is a major cause of acute neurological symptoms in children with significant long-term neurological sequelae. Unlike in the adult population, the clinical presentation of strokes in children may not be stereotyped. Hence, many other differential diagnostic possibilities might have to be considered in the emergency setting. Due to this heterogeneous presentation and the resultant clinical dilemma in the early detection, acute thrombolysis even now remains as a very rarely tried therapeutic option in children. Many case reports over these years have shown consistently good results of acute intravenous thrombolysis in children with tissue plasminogen activator (tPA) administered within the time frame. There are also some recent reports of endovascular interventions. However, unlike in the adult population, class 1 clinical studies and good Randomized controlled trials (RCT) are yet to emerge in children. The absence of age-appropriate safety and outcome data for the commonly used thrombolytic agents in children is another major roadblock for developing clinical guidelines and recommendations for this age group. The ambitious Thrombolysis in Pediatric Stroke (TIPS) trial had to be terminated prematurely due to poor patient enrolment. This review critically looks at the current status of the acute management of ischemic strokes in children with a specific emphasis on thrombolytic therapy. Until we have better evidence-based guidelines for this age group, it will be prudent to develop robust institutional pathways to provide this important intervention for all eligible children with acute strokes.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

